Neisseria gonorrhoeae strains resistant to azithromycin and/or with decreased susceptibility to ceftriaxone are common in China, according to a prevalence study. The study also showed that the prevalence of dual resistance in N. gonorrhoeae isolates increased from 2013 to 2016. The results suggest that dual therapy with azithromycin and ceftriaxone, recommended by WHO and many countries to treat gonorrhea, may not prove effective in China.